Aggressive policies that target the use and promotion of off-label use are needed to prevent the use of drugs for non-approved indications with little benefit or with harmful outcomes. It should be ...

The Food and Drug Administration (FDA) authorizes the marketing of drugs only for uses that the manufacturer has demonstrated to be safe and effective. However, the FDA does not regulate medical ...

The National Comprehensive Cancer Network ® (NCCN ®) announces the latest in its series of Policy Summits, Issues in Off-Label Use and the Applications of Compendia. This NCCN Oncology Policy Summit ...

Dabigatran has been readily integrated into clinical practice in the United States, primarily for treatment of atrial fibrillation (A-fib) but increasingly for off-label indications as well, according ...

In a recent national survey, a substantial minority of physicians erroneously believed that certain off-label uses of prescription drugs were approved by the Food and Drug Administration. This ...